• 1. Achieving crystal-induced room temperature phosphorescence and reversible photochromic properties by strong intermolecular interactions?
  Fuming Xiao,Mengzhu Wang,Yunxiang Lei,Wenbo Dai,Yunbing Zhou,Miaochang Liu,Wenxia Gao,Xiaobo Huang,Huayue Wu J. Mater. Chem. C, 2020,8, 17410-17416
• 2. An AuNPs-functionalized AlGaN/GaN high electron mobility transistor sensor for ultrasensitive detection of TNT?
  Ying Li,Weirong Yao,Yunfei Xie,Renjun Pei RSC Adv., 2015,5, 98724-98729
• 3. An approach to C–N activation: coupling of arenesulfonyl hydrazides and arenesulfonyl chlorides with tert-amines via a metal-, oxidant- and halogen-free anodic oxidation??
  M. Sheykhan,S. Khani,S. Shaabanzadeh,M. Joafshan Green Chem., 2017,19, 5940-5948
• 4. An investigation on the second-order nonlinear optical response of cationic bipyridine or phenanthroline iridium(iii) complexes bearing cyclometallated 2-phenylpyridines with a triphenylamine substituent?
  David B. Cordes,Alexandra M. Z. Slawin,Stefania Righetto,Denis Jacquemin,Eli Zysman-Colman,Véronique Guerchais Dalton Trans., 2018,47, 8292-8300
• 5. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Lactams Beta lactams Cephems

Introduction to Desfuroyl Ceftiofur S-Acetamide (CAS No 120882-25-9)

Desfuroyl Ceftiofur S-Acetamide, a compound with the chemical identifier CAS No 120882-25-9, represents a significant advancement in the field of pharmaceutical chemistry. This compound is a derivative of ceftiofur, a well-known broad-spectrum cephalosporin antibiotic, and has been extensively studied for its potential applications in veterinary medicine and human health. The structural modification of ceftiofur to produce Desfuroyl Ceftiofur S-Acetamide enhances its pharmacological properties, making it a promising candidate for treating various bacterial infections.

The chemical structure of Desfuroyl Ceftiofur S-Acetamide incorporates a desfuroyl group and an S-acetamide moiety, which contribute to its unique mechanism of action. These modifications improve the compound's stability, bioavailability, and efficacy against resistant bacterial strains. Recent studies have highlighted the compound's ability to inhibit bacterial cell wall synthesis, a critical target for effective antibiotic therapy. This mechanism is particularly relevant in the context of rising antibiotic resistance, where novel therapeutic agents are urgently needed.

In veterinary medicine, Desfuroyl Ceftiofur S-Acetamide has shown remarkable promise in treating respiratory infections, such as those caused by *Pasteurella multocida* and *Haemophilus parainfluenzae*. Clinical trials have demonstrated its effectiveness in reducing morbidity and mortality rates in infected animals. The compound's favorable pharmacokinetic profile allows for once-daily dosing, which enhances patient compliance and convenience. Additionally, its minimal side effect profile makes it suitable for long-term treatment regimens.

Research into the pharmacodynamics of Desfuroyl Ceftiofur S-Acetamide has revealed intriguing insights into its interaction with bacterial enzymes. Specifically, studies indicate that the compound targets penicillin-binding proteins (PBPs), which are essential for bacterial cell wall synthesis. By inhibiting these enzymes, Desfuroyl Ceftiofur S-Acetamide effectively disrupts bacterial growth and proliferation. This mechanism is particularly effective against Gram-positive and Gram-negative bacteria, making it a versatile therapeutic option.

Advances in synthetic chemistry have enabled the efficient production of Desfuroyl Ceftiofur S-Acetamide, making it more accessible for clinical use. The synthesis involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Innovations in catalytic methods have further streamlined the production process, reducing costs and environmental impact. These advancements are crucial for ensuring that this vital therapeutic agent remains widely available.

The safety profile of Desfuroyl Ceftiofur S-Acetamide has been thoroughly evaluated through preclinical and clinical studies. Results indicate that the compound is well-tolerated at therapeutic doses, with minimal systemic adverse effects. However, as with any pharmaceutical agent, careful monitoring is recommended during treatment to identify and manage potential side effects. Ongoing research continues to explore the long-term safety implications of this compound, ensuring that it remains a safe and effective treatment option.

Desfuroyl Ceftiofur S-Acetamide also holds potential in combination therapy regimens. Its unique mechanism of action allows it to complement other antibiotics, reducing the risk of resistance development. Combination therapy is increasingly recognized as an essential strategy for combating multidrug-resistant bacteria. By leveraging the synergistic effects of different antibiotics, healthcare providers can achieve more robust and sustainable treatment outcomes.

The regulatory landscape for Desfuroyl Ceftiofur S-Acetamide has been shaped by stringent guidelines aimed at ensuring patient safety and efficacy. Regulatory agencies require comprehensive data on the compound's pharmacological properties before approving its use in clinical practice. These regulations ensure that only high-quality therapeutic agents reach the market, benefiting patients worldwide. The approval process also encourages innovation by providing clear pathways for new drug development.

Future research directions for Desfuroyl Ceftiofur S-Acetamide include exploring its potential applications in human medicine. Preliminary studies suggest that it may be effective against certain human pathogens, offering a new weapon in the fight against bacterial infections. Additionally, researchers are investigating ways to further optimize the compound's properties through structural modifications. These efforts aim to enhance its efficacy while minimizing potential side effects.

The impact of Desfuroyl Ceftiofur S-Acetamide extends beyond veterinary medicine and human health. Its development underscores the importance of interdisciplinary collaboration between chemists, biologists, and medical professionals in addressing global health challenges. By fostering innovation and research excellence, this compound exemplifies how scientific advancements can lead to tangible improvements in healthcare outcomes.

• 68401-81-0(Ceftizoxime)
• 125110-14-7(Cefixime Trihydrate)
• 91832-40-5(Cefdinir)
• 80210-62-4(Cefpodoxime Acid)
• 63527-52-6(Cefotaxime)
• 65052-63-3(Cefetamet)
• 158039-15-7(Desfuroyl Ceftiofur Cysteine Disulfide (Contain 5% Ceftiofur))
• 79350-37-1(Cefixime)
• 88040-23-7(Cefepime)
• 120882-22-6(Desfuroyl Ceftiofur (>85%))